Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum‐based chemotherapy in advanced nonsmall‐cell lung cancer patients

Polymorphism of DNA base excision repair (BER) genes affects DNA repair capacity and may alter sensitivity to platinum‐based chemotherapy regimens. This study investigated polymorphisms of OGG1 Ser326Cys, APE1 Asp148Glu APE1‐141T/G and XRCC1 Arg399Gln for association with clinical outcome in 235 advanced inoperable nonsmall‐cell lung cancer (NSCLC) patients after treatment with platinum‐based chemotherapy. The multivariate analysis showed that OGG1 326 GC was associated with poor PFS [hazard ratio (HR) 1.730, p = 0.005], while XRCC1 399 GA, or GA+AA, was associated with poor OS in short‐term period (HR 1.718, p = 0.003; HR 1.691, p = 0.003, respectively). Patients with OGG1 326/XRCC1 399 variant alleles had a higher risk to die early in short‐term period (HR 1.929, p < 0.001). Furthermore, patients with XRCC1 399 variant allele (GA+AA) had higher risk of hematologic toxicity (p = 0.009), whereas patients carrying the OGG1 326 variant (GG), or the APE1‐141 GG variant, had reduced risk of gastrointestinal toxicity (p = 0.015 and p = 0.023, respectively). The data from the current study provide evidence that OGG1 Ser326Cys, XRCC1 Arg399Gln, APE1 Asp148Glu, and APE1‐141T/G polymorphisms may be useful in predicting clinical outcomes in patients with advanced inoperable NSCLC that will undergo platinum‐based chemotherapy.

[1]  Hongbing Shen,et al.  Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer , 2013, Cancer Chemotherapy and Pharmacology.

[2]  D. Butkiewicz,et al.  Influence of DNA repair gene polymorphisms on prognosis in inoperable non‐small cell lung cancer patients treated with radiotherapy and platinum‐based chemotherapy , 2012, International journal of cancer.

[3]  J. Shih,et al.  Genetic Polymorphism of XRCC1 Arg399Gln Is Associated With Survival in Non–Small-Cell Lung Cancer Patients Treated With Gemcitabine/Platinum , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  E. Smit,et al.  Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapy , 2012, Cancer.

[5]  A. Sigurdson,et al.  Variation in base excision repair capacity. , 2011, Mutation research.

[6]  A. Rossi,et al.  Treatment of advanced non small cell lung cancer. , 2011, Journal of thoracic disease.

[7]  Zeng-peng Li,et al.  Genetic polymorphism of DNA base-excision repair genes (APE1, OGG1 and XRCC1) and their correlation with risk of lung cancer in a Chinese population. , 2011, Archives of medical research.

[8]  W. Pao,et al.  Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer , 2011, Cancer journal.

[9]  Chen Wu,et al.  No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy , 2010, Cancer biology & therapy.

[10]  J. Park,et al.  Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non‐small‐cell lung cancer , 2010, Cancer science.

[11]  P. Guan,et al.  Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma , 2009, BMC Cancer.

[12]  Dong Wang,et al.  APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. , 2009, Lung cancer.

[13]  B. Dalhus,et al.  DNA base repair--recognition and initiation of catalysis. , 2009, FEMS microbiology reviews.

[14]  M. Tsao,et al.  Molecular predictive and prognostic markers in non-small-cell lung cancer. , 2009, The Lancet. Oncology.

[15]  Xinchen Sun,et al.  Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. , 2009, Lung cancer.

[16]  Chien-Jen Chen,et al.  A Polymorphism in the APE1 Gene Promoter is Associated with Lung Cancer Risk , 2009, Cancer Epidemiology Biomarkers & Prevention.

[17]  W. Tan,et al.  XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. , 2008, Lung cancer.

[18]  K. Yoo.  Cancer control activities in the Republic of Korea. , 2008, Japanese journal of clinical oncology.

[19]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[20]  G. Scagliotti,et al.  Prospective Assessment of XPD Lys751Gln and XRCC1 Arg399Gln Single Nucleotide Polymorphisms in Lung Cancer , 2007, Clinical Cancer Research.

[21]  P. Brennan,et al.  Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. , 2005, American journal of epidemiology.

[22]  J. Chang-Claude,et al.  Association between Polymorphisms in the DNA Repair Genes, XRCC1, APE1, and XPD and Acute Side Effects of Radiotherapy in Breast Cancer Patients , 2005, Clinical Cancer Research.

[23]  G. Tell,et al.  The intracellular localization of APE1/Ref-1: more than a passive phenomenon? , 2005, Antioxidants & redox signaling.

[24]  Tomas Lindahl,et al.  Repair and genetic consequences of endogenous DNA base damage in mammalian cells. , 2004, Annual review of genetics.

[25]  G. Fròsina.  CommentaryDNA Base Excision Repair Defects in Human Pathologies , 2004, Free radical research.

[26]  N. Price,et al.  Impact of genetic polymorphisms in DNA repair enzymes on drug resistance in lung cancer. , 2004, Clinical lung cancer.

[27]  D. Neuberg,et al.  XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. G. Donnelly,et al.  Pharmacogenetics in Cancer Chemotherapy: Balancing Toxicity and Response , 2004, Therapeutic drug monitoring.

[29]  S. Groshen,et al.  ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. , 2003, Clinical advances in hematology & oncology : H&O.

[30]  R. Rosell,et al.  DNA repair and cisplatin resistance in non-small-cell lung cancer. , 2002, Lung cancer.

[31]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[32]  F. Oesch,et al.  DNA repair activity of 8-oxoguanine DNA glycosylase 1 (OGG1) in human lymphocytes is not dependent on genetic polymorphism Ser326/Cys326. , 2001, Mutation research.

[33]  D. Wilson,et al.  The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. , 2001, Mutation research.

[34]  N. Hamajima,et al.  PCR-CTPP: a new genotyping technique in the era of genetic epidemiology , 2001, Expert review of molecular diagnostics.

[35]  F. Skorpen,et al.  Base excision repair of DNA in mammalian cells , 2000, FEBS letters.

[36]  M. Dizdaroglu,et al.  Excision of oxidatively damaged DNA bases by the human α-hOgg1 protein and the polymorphic α-hOgg1(Ser326Cys) protein which is frequently found in human populations , 1999 .

[37]  J. Yokota,et al.  Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA , 1998, Oncogene.

[38]  G. Jin,et al.  Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751. , 2011, Asian Pacific journal of cancer prevention : APJCP.

[39]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[40]  R. Rosell,et al.  Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. , 2003, Clinical lung cancer.

[41]  M. Dizdaroglu,et al.  Excision of oxidatively damaged DNA bases by the human alpha-hOgg1 protein and the polymorphic alpha-hOgg1(Ser326Cys) protein which is frequently found in human populations. , 1999, Nucleic acids research.

[42]  John P. Klein,et al.  Estimating the Survival Function in the Proportional Hazards Regression Model: A Study of the Small Sample Size Properties , 1996 .